Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Central Nervous System Bacterial Infections

ClinicalTrials.gov lists 219 trials for Central Nervous System Bacterial Infections or a narrower condition beneath it. Novartis Vaccines has the most among industry and government lead sponsors, with 27.

MeSH D020806 Infections C01 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 44 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 65 Phase 4 Phase 4 21 Not applicable Not applicable 21 Observational Observational 44 Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 44 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 65 Phase 4 Phase 4 21 Not applicable Not applicable 21 Observational Observational 44

Trials per phase

1 of the 219 trials are tagged with Central Nervous System Bacterial Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Central Nervous System Bacterial Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Central Nervous System Bacterial Infections trials start? (27)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 17

1997: 1 trials (Phase 2 1) 1999: 1 trials (Phase 2 1) 2002: 2 trials (Observational 1, Phase 3 1) 2003: 2 trials (Observational 1, Phase 4 1) 2004: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2005: 5 trials (Not applicable 1, Phase 2 3, Phase 1 1) 2006: 7 trials (Observational 1, Phase 3 3, Phase 2 2, Phase 1 1) 2007: 7 trials (Phase 3 6, Phase 1/2 1) 2008: 8 trials (Observational 2, Phase 3 4, Phase 2 1, Phase 1/2 1) 2009: 9 trials (Not applicable 2, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2010: 13 trials (Observational 3, Phase 3 4, Phase 2/3 1, Phase 2 5) 2011: 13 trials (Observational 3, Phase 4 2, Phase 3 5, Phase 2 2, Phase 1 1) 2012: 9 trials (Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 1) 2013: 7 trials (Observational 1, Phase 3 3, Phase 2 3) 2014: 7 trials (Observational 1, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1 1) 2015: 12 trials (Observational 4, Not applicable 2, Phase 4 3, Phase 3 1, Phase 2 1, Phase 1 1) 2016: 11 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 1) 2017: 12 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2018: 17 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1 3) 2019: 11 trials (Observational 3, Not applicable 3, Phase 4 2, Phase 3 2, Phase 2 1) 2020: 9 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 2) 2021: 11 trials (Observational 2, Not applicable 2, Phase 3 3, Phase 2/3 1, Phase 2 3) 2022: 1 trials (Observational 1) 2023: 7 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 2) 2024: 10 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1/2 1) 2025: 7 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 15
2025 7
2024 10
2023 7
2022 1
2021 11
2020 9
2019 11
2018 17
2017 12

Showing 10 of 27 earlier years.

Start your 14-day trial Email me all 27 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 18 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 20 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 145 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Central Nervous System Bacterial Infections trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 13
Phase 1/2 5
Phase 2 44
Phase 2/3 6
Phase 3 65
Phase 4 21
Not applicable 21
Observational 44

How many Central Nervous System Bacterial Infections trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 10
Recruiting 22
Enrolling by invitation 1
Active, not recruiting 6
Completed 144

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Central Nervous System Bacterial Infections trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Vaccines 27
Sanofi Pasteur, a Sanofi Company 23
Pfizer 10
GlaxoSmithKline 9
CanSino Biologics Inc. 8

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Interventions as named in the registry (15)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 8
MenACWY CRM 7
Ceftriaxone 4g/ 24h 6
Meningococcal ACWY Conjugate Vaccine 6
MCV4 6

Showing 5 of 15 interventions.

Start your 14-day trial Email me all 15 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Central Nervous System Bacterial Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Gastroenteritis 131 17
Bronchitis 91 8
BRONCHIOLITIS 87 2
Bronchiolitis 79 13
Pneumonia 70 21

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Central Nervous System Bacterial Infections? (4)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Infection rate and risk factors associated with infections related to external ventricular drain. Infection 2011 Yes
Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomised clinical trial. Journal of neurology, neurosurgery, and psychiatry 2010 Yes
Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: findings from a preliminary waitlist controlled open trial. Journal of the American Academy of Child and Adolescent Psychiatry 2006 Yes
The Rate of Complications after Ventriculoperitoneal Shunt Surgery. World neurosurgery 2017 No

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages